OTCM
YECO
Market cap0kUSD
Oct 07, Last price
0.00USD
1D
0.00%
1Q
-75.00%
IPO
-99.83%
Name
Yulong Eco-Materials Ltd
Chart & performance
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
9.74%
Rev. gr., 5y
-65.12%
Revenues
178k
+264.75%
Net income
-299k
L-76.44%
CFO
-126k
L-96.15%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
EV Biologics, Inc. is a biotechnology enterprise focused on the commercial advancement of extracellular vesicles (EVs), utilizing them as biological agents for diagnostic and therapeutic applications. The company capitalizes on its proprietary, versatile EV platform to engineer innovative vaccines, treatments, and potential cures. Beyond EVs, it also dedicates efforts to cultivating human mesenchymal and other stem cells, as well as various cell-derived products, to address the needs of the cosmetic and biopharmaceutical industries. Founded in 2011, the firm was originally known as Yulong Eco-Materials Limited until its rebranding to EV Biologics, Inc. in August 2020, and it operates from its headquarters in Cheyenne, Wyoming.
Key people
Wancheng Xie
Chairman of the Board · since 2018
Yulong Zhu
Chief Executive Officer · since 2018
Shuai Wang
Chief Financial Officer · since 2017
Hong Jiang
Director
Wenge Du
Independent Director · since 2017
Yang Li
Independent Director · since 2017
Qiang Liu
Independent Director · since 2015
Qingsheng Liu
Independent Director · since 2017
Junfeng Ma
Independent Director · since 2017
IPO date
Jun 29, 2015
Employees
284
Domiciled in
CN
Incorporated in
KY
Headquarters & legal address
C/O Abacus Management Limited
PO Box 2499
Ground Floor
Elizabethan Square
George Town KY1-1104
KY
PO Box 2499
Ground Floor
Elizabethan Square
George Town KY1-1104
KY
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2017‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||